Table 2.
Median MRD level at EOT and median MRD doubling time post-EOT according to biological factors
| Parameter | VenR (n = 91) | BR (n = 120) | ||
|---|---|---|---|---|
| Median MRD at EOT | mut-IGHV (n = 22) |
unmut-IGHV (n = 69) |
mut-IGHV (n = 33) |
unmut-IGHV (n = 87) |
| 3.40 × 10−5 | 1.88 × 10−5 | 1.11 × 10−3 | 4.46 × 10−4 | |
| P = .79 | P = .6 | |||
|
TP53-WT* (n = 73) |
TP53-mut* (n = 18) |
TP53-WT* (n = 98) |
TP53-mut* (n = 22) |
|
| 1.87 × 10−5 | 3.56 × 10−5 | 1.94 × 10−2 | 3.07 × 10−2 | |
| P = .48 | P = .002 | |||
| Median MRD doubling time, d | mut-IGHV (n = 22) |
unmut-IGHV (n = 69) |
mut-IGHV (n = 33) |
unmut-IGHV (n = 87) |
| 192 | 80 | 57 | 52 | |
| P = .0031 | P = .093 | |||
|
TP53-WT* (n = 73) |
TP53-mut* (n = 18) |
TP53-WT* (n = 98) |
TP53-mut* (n = 22) |
|
| 101 | 66 | 54 | 45 | |
| P = .0012 | P = .072 | |||
| Age ≥65 y (n = 44) |
Age <65 y (n = 47) |
Age ≥65 y (n = 75) |
Age <65 y (n = 45) |
|
| 109 | 80 | 57 | 43 | |
| P = .012 | P = .0036 | |||
| Low/medium TLS risk (n = 65) | High TLS risk (n = 26) |
Low/medium TLS risk (n = 86) | High TLS risk (n = 34) |
|
| 105 | 63 | 56 | 51 | |
| P = .0001 | P = .02 | |||
TLS, tumor lysis syndrome.
*
TP53 status only [not considering del(17p)].